Bio-Rad Laboratories (BIO) Cash from Operations (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Cash from Operations for 18 consecutive years, with $98.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 15.28% year-over-year to $98.7 million in Q2 2026; TTM through Jun 2026 was $492.6 million, a 7.79% decrease from a year earlier, with the FY2025 full-year figure at $532.2 million, up 16.92% from the prior year.
• Cash from Operations was $98.7 million for Q2 2026 at Bio-Rad Laboratories, down from $108.1 million in the prior quarter.
• Over five years, Cash from Operations peaked at $164.9 million in Q4 2025 and troughed at $11.0 million in Q3 2022.
• A 5-year average of $98.0 million and a median of $98.1 million in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations plunged 95.22% in 2022 and jumped 788.18% in 2023, its largest moves.
• Over 5 years, Cash from Operations stood at $79.6 million in 2022, then increased by 1.76% to $81.0 million in 2023, then soared by 53.33% to $124.2 million in 2024, then jumped by 32.77% to $164.9 million in 2025, then plunged by 40.15% to $98.7 million in 2026.
• The last three Cash from Operations figures came in at $98.7 million (Q2 2026), $108.1 million (Q1 2026), and $164.9 million (Q4 2025), per Business Quant data.